Searchable abstracts of presentations at key conferences in endocrinology

ea0039ep19 | Bone | BSPED2015

Rickets due to dietary calcium deficiency in Manchester

Juma Fatema Zehra , Santos Rui , Mughal M Zulf

Background and aims: Rickets is a childhood condition resulting from impaired mineralisation of the growth plate, resulting in bony deformities. A retrospective survey was undertaken to identify causes of rickets in children treated at the Royal Manchester Children’s Hospital from 2009 to 2014.Methods: Cases of rickets were identified through a search of all paediatric radiology reports containing the words ‘Rickets’ or ‘Osteomalacia&...

ea0066oc5.6 | Oral Communications 5 | BSPED2019

Monitoring and long-term disease activity in children with X-linked hypophosphataemia on conventional therapy

Uday Suma , Shaw Nick , Mughal Zulf , Randell Tabitha , Hogler Wolfgang , Santos Rui , Padidela Raja

Background: Conventional treatment of X-linked hypophosphataemic rickets (XLH) involves administration of oral phosphate and vitamin D analogues. Newer therapies such as Anti Fibroblast Growth Factor 23 antibodies (burosumab) have now become available. An important treatment goal is to heal rickets; assessed by normalisation of serum alkaline phosphatase (ALP) levels and resolution of radiological signs of rickets.Objectives: (1) Assess disease severity ...

ea0066p8 | Bone | BSPED2019

Clinical, functional and quality of life outcomes of Burosumab therapy in children with X-linked hypophosphoataemia: a real world, London experience

Sandy Jessica , Gilbey-Cross Robyn , Santos Rui , Sakka Sophia , Cocca Alessandra , Morris Mavali , Massey Jill , Cheung Moira

Burosumab, monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We explored the effects of this treatment in a clinical setting, considering biochemistry, growth, deformity, functionality, quality of life, pain and fatigue.Methods: Clinical, biochemical, radiological and questionnaire data were reviewed at 6 and 12 months(m) for 8 children with XLH starting burosuma...